A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Stopped DSMB recommendation due to lack of efficacy. There were no safety signals.

Conditions

• HER-2 Gene Amplification
• Esophagus Cancer
• Gastroesophageal Junction Cancer
• Stomach Cancer

Interventions

• DRUG: MM-111
• DRUG: Paclitaxel
• DRUG: Trastuzumab

Sponsor

Merrimack Pharmaceuticals